Skip to main content
. 2020 Jun 25;12(6):1690. doi: 10.3390/cancers12061690

Figure 4.

Figure 4

Cumulative bRF survival function adjusted by risk factors of high-risk patients; with and without ADT (a) and with ADT for 1–6 months and with ADT >6 months (b). The two lines other than “<6” overlap. bRF, biochemical relapse-free; ADT, androgen deviation therapy; HR, hazard ratio; CI, confidence interval. a Cox regression analysis of the two groups with ADT.